Stock Research for NVS

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

NVS Stock Chart & Research Data

The NVS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the NVS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


NVS Due diligence Resources & Stock Charts

The NVS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View NVS Detailed Price Forecast - CNN Money CNN View NVS Detailed Summary - Google Finance
Yahoo View NVS Detailed Summary - Yahoo! Finance Zacks View NVS Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View NVS Trends & Analysis - Trade-Ideas Barrons View NVS Major Holders - Barrons
NASDAQ View NVS Call Transcripts - NASDAQ Seeking View NVS Breaking News & Analysis - Seeking Alpha
Spotlight View NVS Annual Report - CompanySpotlight.com OTC Report View NVS OTC Short Report - OTCShortReport.com
TradeKing View NVS Fundamentals - TradeKing Charts View NVS SEC Filings - Bar Chart
WSJ View Historical Prices for NVS - The WSJ Morningstar View Performance/Total Return for NVS - Morningstar
MarketWatch View the Analyst Estimates for NVS - MarketWatch CNBC View the Earnings History for NVS - CNBC
StockMarketWatch View the NVS Earnings - StockMarketWatch MacroAxis View NVS Buy or Sell Recommendations - MacroAxis
Bullish View the NVS Bullish Patterns - American Bulls Short Pains View NVS Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View NVS Stock Mentions - StockTwits PennyStocks View NVS Stock Mentions - PennyStockTweets
Twitter View NVS Stock Mentions - Twitter Invest Hub View NVS Investment Forum News - Investor Hub
Yahoo View NVS Stock Mentions - Yahoo! Message Board Seeking Alpha View NVS Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for NVS - SECform4.com Insider Cow View Insider Transactions for NVS - Insider Cow
CNBC View NVS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for NVS - OTC Markets
Yahoo View Insider Transactions for NVS - Yahoo! Finance NASDAQ View Institutional Holdings for NVS - NASDAQ


Stock Charts

FinViz View NVS Stock Insight & Charts - FinViz.com StockCharts View NVS Investment Charts - StockCharts.com
BarChart View NVS Stock Overview & Charts - BarChart Trading View View NVS User Generated Charts - Trading View


Latest Financial News for NVS

Is Biopharma Investing Too Much In Cancer R&D?
Posted on Tuesday April 24, 2018

Jay Bradner is the president of Novartis’ Institutes for BioMedical Research, the organization entrusted with Novartis’ R&D budget of $9 billion -- one of the largest in the industry. Furthermore, Novartis is a leading innovator in the oncology field with targeted therapies as well as the recently launched CAR-T therapy Kymriah for a deadly childhood leukemia. This is a time of extraordinary promise for cancer medicine, with unambiguous evidence of progress in the innovation of both targeted and immune-oncology therapies.


Shire (SHPG) Turns Down Takeda's Third Buyout Proposition
Posted on Friday April 20, 2018

Shire (SHPG) declines Takeda Pharmaceutical's third acquisition offer in a cash-stock deal.


What's in the Cards for Glaxo (GSK) This Earnings Season?
Posted on Friday April 20, 2018

Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might aid the company's results in Q1.


Novartis (NVS) Reports Encouraging Data on MS Candidate
Posted on Friday April 20, 2018

Novartis (NVS) announces encouraging results from a phase III study, EXPAND, on siponimod (BAF312) in patients with secondary progressive multiple sclerosis.


Enter a stock symbol to view the stock details.